Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.68% | 29.06% | 30.24% | 90.13% | 225.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.68% | 29.06% | 30.24% | 90.13% | 225.80% |
| Cost of Revenue | 14.66% | 47.92% | 57.51% | 166.38% | 267.13% |
| Gross Profit | -7.93% | 12.93% | 14.57% | 47.88% | 191.15% |
| SG&A Expenses | -60.30% | -29.37% | -31.19% | -31.41% | 94.68% |
| Depreciation & Amortization | 107.19% | 159.14% | 168.66% | 56.84% | -72.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.81% | -12.68% | -11.63% | -7.74% | 39.82% |
| Operating Income | 65.94% | 33.28% | 36.81% | 48.73% | -8.89% |
| Income Before Tax | 56.32% | 17.64% | 25.06% | 44.19% | 23.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.32% | 17.64% | 25.06% | 44.19% | 23.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.32% | 17.64% | 25.06% | 44.19% | 23.13% |
| EBIT | 65.94% | 33.28% | 36.81% | 48.73% | -8.89% |
| EBITDA | 68.44% | 33.25% | 37.93% | 49.99% | -16.95% |
| EPS Basic | 59.14% | 22.50% | -12.31% | 48.68% | 33.09% |
| Normalized Basic EPS | 60.34% | 22.00% | -12.20% | 48.94% | 7.94% |
| EPS Diluted | 59.14% | 22.50% | -12.31% | 48.68% | 33.09% |
| Normalized Diluted EPS | 60.34% | 22.00% | -12.20% | 48.94% | 7.94% |
| Average Basic Shares Outstanding | 8.76% | 6.04% | -32.95% | 7.90% | 14.55% |
| Average Diluted Shares Outstanding | 8.76% | 6.04% | -32.95% | 7.90% | 14.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |